Cediranib
Hormone-Resistant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsSmall moleculePhase 2Dormant
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Hormone-Resistant Prostate Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Docetaxel Seattle Institute for Biomedical and Clinical Research | Phase 3 | BB |
Enzalutamide Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 3 | BB |
Cyclophosphamide University of Wisconsin, Madison | Phase 2 | BB |
Pembrolizumab University of Wisconsin, Madison | Phase 2 | B |
Epirubicin University of Wisconsin, Madison | Phase 2 | B |
View all 26 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →